Increasing Demand for Effective Drug Discovery Techniques to Augment the Label-Free Array Systems Market Growth
Label-free array systems include two types of biosensors such as optical and impedance-based biosensors, including techniques such as isothermal titration calorimetry (ITC), surface plasmon resonance (SPR), bio-layer interferometry, etc. These systems have many applications such as diagnostics, drug development, etc.
Label-free array systems are widely used in the drug
discovery process by biotechnology and pharmaceutical companies. The system
works on the principle of optical interferometry, impedance-based assays, and refractive
index to identify and validate new molecules as the possible drug candidates.
Moreover, Label-free array systems help reduce the cost and time for drug
identification and validation process.
Market Dynamics:
Increasing demand for effective drug discovery techniques,
due to increasing prevalence of chronic diseases, is expected to propel the
growth of the label-free array systems market. For instance, according to the
world Health Organization (WHO), chronic diseases are the leading causes of
death and disability worldwide.
Moreover, rapid growth of the pharmaceutical industry and
the increasing adoption of label-free array systems in the drug discovery is
expected to drive the label-free array systems market growth.
The increase in research and
development activities is also expected to augment the growth of the label-free
array systems market. For instance, in
November/December 2020, a research team from the California Institute of
Technology developed a two-dimensional (2D) multifocal optical resolution
photoacoustic microscopy system. The system has potential for numerous
biomedical applications, such as UV illumination for high-speed, label-free
histological study of biological tissues.
The label-free array
systems market is witnessing significant merger
and acquisition (M&A) activities. For instance, in June 2018, Bruker
acquired Sierra Sensors to expand real-time, label-free detection portfolio for
Pharma and Biopharma drug discovery.
However, high cost associated
with this technology and lack of knowledge and information about this system is
expected to hinder the market growth restrain the growth of the label-free
array systems market.
Competitive Analysis:
Major players active in the label-free array systems market
are Bruker Corporation, Biosensing Instrument, NanoSPR Devices, Nicoya, plasmetrix.com,
ABL&E Group, Horiba instruments Incorporated, Metrohm India Limited, Reichert,
BioNavis Ltd, and General Electric Healthcare.
Major players in the market are involved in different
business strategies, such as business expansion, to enhance their market
presence. For instance, in October 2020, Axol Bioscience (Axol) announced the
expansion of its service offering, with the introduction of multi-electrode
array screening for human iPSC-derived cells to support pre-clinical research
by optimizing human iPSC-derived cell culture, providing high-quality electrophysiological
data acquisition and analysis from physiologically relevant human cell models.
Comments
Post a Comment